Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization
Open Access
- 1 March 2020
- journal article
- research article
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section F Structural Biology Communications
- Vol. 76 (3) , 116-129
Abstract
Immunoglobulin E (IgE) plays a central role in the allergic response, in which cross-linking of allergen by Fc∊RI-bound IgE triggers mast cell and basophil degranulation and the release of inflammatory mediators. The high-affinity interaction between IgE and Fc∊RI is a long-standing target for therapeutic intervention in allergic disease. Omalizumab is a clinically approved anti-IgE monoclonal antibody that binds to free IgE, also with high affinity, preventing its interaction with Fc∊RI. All attempts to crystallize the pre-formed complex between the omalizumab Fab and the Fc region of IgE (IgE-Fc), to understand the structural basis for its mechanism of action, surprisingly failed. Instead, the Fab alone selectively crystallized in different crystal forms, but their structures revealed intermolecular Fab/Fab interactions that were clearly strong enough to disrupt the Fab/IgE-Fc complexes. Some of these interactions were common to other Fab crystal structures. Mutations were therefore designed to disrupt two recurring packing interactions observed in the omalizumab Fab crystal structures without interfering with the ability of the omalizumab Fab to recognize IgE-Fc; this led to the successful crystallization and subsequent structure determination of the Fab/IgE-Fc complex. The mutagenesis strategy adopted to achieve this result is applicable to other intractable Fab/antigen complexes or systems in which Fabs are used as crystallization chaperones.Keywords
Funding Information
- Medical Research Council (G1100090)
- Wellcome Trust (085944)
This publication has 62 references indexed in Scilit:
- Structural basis for selective inhibition of immunoglobulin E-receptor interactions by an anti-IgE antibodyScientific Reports, 2018
- Allosteric mechanism of action of the therapeutic anti-IgE antibody omalizumabJournal of Biological Chemistry, 2017
- IgE binds asymmetrically to its B cell receptor CD23Scientific Reports, 2017
- A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthmamAbs, 2014
- New concepts and aids to facilitate crystallizationCurrent Opinion in Structural Biology, 2013
- Mapping of the CD23 Binding Site on Immunoglobulin E (IgE) and Allosteric Control of the IgE-FcϵRI InteractionJournal of Biological Chemistry, 2012
- MolProbity: all-atom structure validation for macromolecular crystallographyActa Crystallographica Section D Structural Biology, 2009
- Three-dimensional structure of an immunoglobulin light-chain dimer with amyloidogenic propertiesActa Crystallographica Section D Structural Biology, 2002
- Bent Domain Structure of Recombinant Human IgE-Fc in Solution by X-ray and Neutron Scattering in Conjunction with an Automated Curve Fitting ProcedureBiochemistry, 1995
- A model for the solution conformation of rat IgEBiochemical Society Transactions, 1990